MicroRNAs are central regulators of DLBCL biology and show strong potential as minimally invasive biomarkers to improve ...

Please provide your email address to receive an email when new articles are posted on . In this video, Leo I. Gordon, MD, FACP, discusses highlights from a debate at Lymphoma, Leukemia & Myeloma ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma ...

Recent advancements in treatment options for patients with diffuse large B-cell lymphoma have been practice-changing. He wasn’t expecting a fall during an ice storm to lead to a cancer diagnosis. But ...

The FDA approved Epkinly in combination with other standard lymphoma drugs, rituximab + lenalidomide, for relapsed or refractory follicular lymphoma.

In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat ...

Effective integration of bispecific antibodies in follicular lymphoma relies on comprehensive education for both patients and healthcare providers. Patients benefit from clear explanations about ...

"Typically, patients will present with motor weakness, sensory deficits, and pain in nerve sites affected by NL. The most common nerve sites include the cauda equina nerves, the brachial plexus, the ...